Skip to main content
Clinical Trials/NCT03244514
NCT03244514
Completed
Not Applicable

Biomarker-guided Implementation of the Cardiovascular (CV) Surgery AKI Bundle to Reduce the Occurrence of AKI After Cardiac Surgery- Prevention of AKI

University Hospital Muenster12 sites in 5 countries280 target enrollmentNovember 2, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acute Kidney Injury (Nontraumatic)
Sponsor
University Hospital Muenster
Enrollment
280
Locations
12
Primary Endpoint
Compliance rate
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

There is no specific therapy for acute kidney injury. It is presumed that supportive measures improve the care and outcome of patients with acute kidney injury.

The investigators hypothesize that the implementation of a bundle of supportive measures adapted to patients undergoing cardiovascular surgery reduces the occurence of AKI.

A Randomized prospective multicenter trial is needed to investigate whether the implementation of the bundle of measures is effective to prevent AKI in high risk patients undergoing cardiac surgery. In this feasibility trial the investigators will analyze the compliance rate to the trial protocol in a multicenter, multinational cohort in preparation for a large randomized controlled trial.

Registry
clinicaltrials.gov
Start Date
November 2, 2017
End Date
January 26, 2020
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
University Hospital Muenster
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adult patients undergoing cardiac surgery with cardiopulmonary bypass (CPB)
  • Urinary \[TIMP-2\] \* \[IGFBP7\] \>= 0.3 4h after CPB
  • Written informed consent

Exclusion Criteria

  • Preexisting AKI (stage 1 and higher)
  • Patients with cardiac assist devices (ECMO, LVAD, RVAD, IABP)
  • Pregnancy, breastfeeding
  • Known (Glomerulo-)-Nephritis, intersstitial nephritis or vasculitis
  • CKD with eGFR \< 20 mL/min
  • Dialyses dependent CKD
  • Prior kidney transplant within the last 12 months

Outcomes

Primary Outcomes

Compliance rate

Time Frame: 48 hours after start of intervention

proportion of patients who are treated according to the trial protocol: CV surgery AKI bundle fulfilled at all time

Secondary Outcomes

  • Free-days through of vasoactive medications and mechanical ventilation(28 days after start of intervention)
  • Renal recovery(90 days after start of intervention)
  • Moderate and severe AKI(72 hours after start of intervention)
  • Occurence of AKI(72 hours after start of intervention)
  • ICU and hospital stay(up to 1 year after start of intervention (until discharge))
  • Mortality(90 days after start of intervention)
  • Number of patients with renal replacement therapy(90 days after start of intervention)

Study Sites (12)

Loading locations...

Similar Trials